Coapt is the leading developer of advanced control solutions for prosthetics. Their primary product is a pattern recognition intent decoder system, called Complete Control, designed to enhance the functionality and user experience of upper-limb prostheses, allowing seamless and personalized movements. The pattern recognition system uses machine learning algorithms, a form of artificial intelligence, or AI, to interpret electrical signals from the residual muscles of the amputee, which are then translated into movement. Complete Control continuously analyzes these signals, known as electromyographic signals, or EMG, to determine the intended movements of the user, allowing for more natural and intuitive control of the prosthetic limb.

Integrum is developing the e-OPRA[TM] Implant System, the world's first upper-limb prosthetic control system using wired tissue-embedded electrodes. e-OPRA[TM] uses an implanted electrode system that both record and stimulate nerves and muscle tissues. By connecting this system with Coapt's pattern recognition technology, Integrum aims to further improve the functionality of e-OPRA[TM].

"Coapt systems have been a complementary technology to prostheses users with Integrum's OPRA[®] Implant System for some time now. This agreement further strengthens the working collaboration between our two companies and will result in the best possible solutions and future with e-OPRA[TM ]and Coapt." Says Blair Lock, CEO of Coapt.

"By complementing the current control system of the e-OPRA[TM] with Coapt's world leading pattern recognition system, we aim to refine the movement control of our implant system further and improve prothesis control. Together with Coapt, I am convinced we will deliver the best possible options for arm amputees, outperforming today's technology. It might sound like science fiction, but it is happening now!" says Rickard Brånemark, CEO of Integrum.